How do ear infections happen? It's pretty simple. Sometimes, germs, like a virus or bacteria, can infect the inside of your ear. This can happen to anyone, although middle ear infections are more ...

Commensal species that can, and do, cause drug-refractory systemic infections (e.g., Candida glabrata). There are significant geographical variations in fungal epidemiology and resistance ...

Podiatrists are encouraging people to be conscious of the risk of picking up toenail fungal infections this summer. Some podiatrists say they have seen an increase in toenail fungal infections ...

“We are also really interested in studying how inhalation of fungal spores – of which we inhale thousands every day – alter susceptibility to viral infection and allergy,” Hilligan sai ...

Trichomoniasis is the most common non-viral STI in the United States, affecting women four times more often than men. An estimated 1 million new trichomoniasis infections occur each year. Caused by ...

China describes the rise in respiratory infections as a common seasonal trend during winter despite reports of a flu outbreak overwhelming hospitals. Authorities maintain that the situation is ...

A 32 year-old man has developed a life-threatening blood infection caused by mould, after living in a fungus-infected property where spores were 'covered up' with paint. Matthew Langsworth ...

Hyaluronidase is an enzyme that facilitates subcutaneous absorption of the active drug nivolumab. The subcutaneous version could transform the way care is delivered to patients, as it allows ...

Fungus in eye drops can cause eye infections, which may be vision-threatening, and potentially life-threatening in immunocompromised people. The FDA is urging consumers to stop using the eye drops ...

In the fixed cutaneous form of the disease there is no spread of infection from the site of fungus inoculation. These lesions can be verrucose in nature. In the other form there can be a general ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...